150 related articles for article (PubMed ID: 21434378)
1. [Prospects for using ladasten preparations in patients with irritable bowel syndrome].
Uspenskiĭ IuP; Fominykh IuA
Eksp Klin Gastroenterol; 2010; (10):75-9. PubMed ID: 21434378
[TBL] [Abstract][Full Text] [Related]
2. [Pilot clinical trial of ladasten].
Siuniakov SA; Grishin SA; Teleshova ES; Neznamov GG; Seredenin SB
Eksp Klin Farmakol; 2006; 69(4):10-5. PubMed ID: 16995430
[TBL] [Abstract][Full Text] [Related]
3. [Treatment experience of patients with irritable bowel syndrome complicated by constipations with medicinal preparation softovak].
Ruchkina IN; Lychkova AE; Parfenov AI
Eksp Klin Gastroenterol; 2007; (5):103-6. PubMed ID: 18389606
[No Abstract] [Full Text] [Related]
4. [Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten].
Voznesenskaia TG; Fokina NM; Iakhno NN
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 1):17-26. PubMed ID: 21322821
[TBL] [Abstract][Full Text] [Related]
5. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study.
Lu WZ; Gwee KA; Moochhalla S; Ho KY
Aliment Pharmacol Ther; 2005 Nov; 22(10):927-34. PubMed ID: 16268966
[TBL] [Abstract][Full Text] [Related]
6. [Drug treatment for irritable bowel syndrome].
Hillilä M; Färkkilä M
Duodecim; 2004; 120(20):2453-8. PubMed ID: 15641514
[No Abstract] [Full Text] [Related]
7. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome.
Dumitraşcu DL; Stănculete M
Rom J Intern Med; 2006; 44(3):273-80. PubMed ID: 18386606
[TBL] [Abstract][Full Text] [Related]
8. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome.
Piche T; Ducrotté P; Sabate JM; Coffin B; Zerbib F; Dapoigny M; Hua M; Marine-Barjoan E; Dainese R; Hébuterne X
Neurogastroenterol Motil; 2010 Jun; 22(6):626-e174. PubMed ID: 20403099
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten].
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Suppl 1):17-26. PubMed ID: 20559263
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
11. [Meteospazmil for correction of motor disorders in functional colon diseases].
Agafonova NA; Iakovenko EP; Ivanov AN; Prianishnikova AS; Iakovenko AV
Eksp Klin Gastroenterol; 2009; (4):101-6. PubMed ID: 19961001
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome.
Klooker TK; Kuiken SD; Lei A; Boeckxstaens GE
Aliment Pharmacol Ther; 2007 Aug; 26(4):605-15. PubMed ID: 17661764
[TBL] [Abstract][Full Text] [Related]
13. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
14. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
Khoshoo V; Armstead C; Landry L
Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
[TBL] [Abstract][Full Text] [Related]
15. Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain.
Williams RE; Hartmann KE; Sandler RS; Miller WC; Savitz LA; Steege JF
Am J Obstet Gynecol; 2005 Mar; 192(3):761-7. PubMed ID: 15746669
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
[TBL] [Abstract][Full Text] [Related]
17. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome.
Sidhu R; McAlindon ME; Leeds JS; Skilling J; Sanders DS
J Gastrointestin Liver Dis; 2009 Mar; 18(1):23-6. PubMed ID: 19337629
[TBL] [Abstract][Full Text] [Related]
18. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
19. Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study.
Ringström G; Störsrud S; Posserud I; Lundqvist S; Westman B; Simrén M
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):420-8. PubMed ID: 19923998
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
